Molecular Autism · 2012 · 357 citations · 36 references
EducationPharmacologyPsychologyAutism Spectrum DisordersPsychopharmacologySocial CognitionBehavior TherapyCognitive Behavioral TherapyNeurodevelopmental DisordersOxytocin PhysiologyPsychosocial InterventionsRepetitive BehaviorsAutism Spectrum Disorder InterventionOxytocin UseRepetitive Behavior AssessmentSocial Cognition DeficitsSocial Cognition ImpairmentSocial Functioning AssessmentSocial Functioning ImpairmentSocial Responsiveness
BACKGROUND: There are no effective medications for the treatment of social cognition/function deficits in autism spectrum disorder (ASD), and adult intervention literature in this area is sparse. Emerging data from animal models and genetic association studies as well as early, single-dose intervention studies suggest that the oxytocin system may be a potential therapeutic target for social cognition/function deficits in ASD. The primary aim of this study was to examine the safety/therapeutic effects of intranasal oxytocin versus placebo in adults with ASD, with respect to the two core symptom domains of social cognition/functioning and repetitive behaviors. METHODS: This was a pilot, randomized, double-blind, placebo-controlled, parallel design trial of intranasal oxytocin versus placebo in 19 adults with ASD (16 males; 33.20 ± 13.29 years). Subjects were randomized to 24 IU intranasal oxytocin or placebo in the morning and afternoon for 6 weeks. Measures of social function/cognition (the Diagnostic Analysis of Nonverbal Accuracy) and repetitive behaviors (Repetitive Behavior Scale Revised) were administered. Secondary measures included the Social Responsiveness Scale, Reading-the-Mind-in-the-Eyes Test and the Yale Brown Obsessive Compulsive Scale - compulsion subscale and quality of life (World Health Organization Quality of Life Questionnaire - emotional/social subscales). Full-information maximum-likelihood parameter estimates were obtained and tested using mixed-effects regression analyses. RESULTS: Although no significant changes were detected in the primary outcome measures after correcting for baseline differences, results suggested improvements after 6 weeks in measures of social cognition (Reading-the-Mind-in-the-Eyes Test, p = 0.002, d = 1.2), and quality of life (World Health Organization Quality of Life Questionnaire - emotion, p = 0.031, d = 0.84), both secondary measures. Oxytocin was well tolerated and no serious adverse effects were reported. CONCLUSIONS: This pilot study suggests that there is therapeutic potential to daily administration of intranasal oxytocin in adults with ASD and that larger and longer studies are warranted. TRIAL REGISTRATION: NCT00490802.
36
Catherine Lord, Michael Rutter, Ann Le Couteur · Journal of Autism and Developmental Disorders · 1994 · 9.1K citations
Education, Psychiatry, Psychology +13
The Yale-Brown Obsessive Compulsive Scale
Wayne K. Goodman · Archives of General Psychiatry · 1989 · 7.6K citations
Catherine Lord, Susan Risi, Linda Lambrecht et al. · Journal of Autism and Developmental Disorders · 2000 · 7.6K citations
Suzanne M. Skevington, Mohamed Lotfy, Kathryn A. O’Connell · Quality of Life Research · 2004 · 4.6K citations
Simon Baron‐Cohen, Sally Wheelwright, Jacqueline Hill et al. · Journal of Child Psychology and Psychiatry · 2001 · 4.4K citations